Vanda Pharmaceuticals Inc.

TickerCurrent Price% Daily ChangeVolume (1,000s)Average Volumn (1,000s)Market Cap (Millions)1/2/2024 Price% Change Since Inception 1/2/2024
VNDA$5.98-5.757%1,7932,617$348$4.5232.2%

Contact Information

Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States

Vanda Pharmaceuticals is a biopharmaceutical company that develops and sells treatments for central nervous system disorders. The company’s goal is to improve patients’ lives by addressing unmet medical needs. Vanda’s products include:
  • Fanapt: An antipsychotic used to treat schizophrenia in adults
  • Hetlioz: A melatonin receptor agonist used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)
Vanda’s other products include Tradipitant (VLY-686), VTR-297, VQW-765, and CFTR, which are part of a portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. The company’s CEO, Mihales Polymeropoulos, MD, founded Vanda in 2003 with Care Capital LLC and Bio*One Capital. Vanda is headquartered in Washington, DC